Maks_Lab
Shares of Guardant Health (NASDAQ:GH) fell 11% Monday morning within the wake of news that the corporate had entered right into a $400M at-the-market stock sale settlement.
Late Friday, Guardant stated in a submitting that it had entered into an open market sale settlement with Jefferies for an ATM program that would generate gross proceeds of as much as $400M.
Guardant lately launched a blood-based take a look at known as Shield for the detection of colorectal most cancers. The product will probably compete in opposition to stool-based assessments marketed by Exact Sciences (EXAS) and Geneoscopy.
Source: Seekingalpha